SORL1
Basic information
Region (hg38): 11:121452314-121633763
Previous symbols: [ "C11orf32" ]
Links
Phenotypes
GenCC
Source:
- early-onset autosomal dominant Alzheimer disease (Supportive), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (11 variants)
- Complex hereditary spastic paraplegia (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SORL1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 98 | 30 | 133 | |||
missense | 318 | 33 | 13 | 364 | ||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 7 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 2 | |||||
splice region | 13 | 17 | 6 | 36 | ||
non coding | 49 | 29 | 80 | |||
Total | 12 | 1 | 326 | 180 | 72 |
Highest pathogenic variant AF is 0.0000197
Variants in SORL1
This is a list of pathogenic ClinVar variants found in the SORL1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-121452346-C-A | not specified | Uncertain significance (Dec 08, 2023) | ||
11-121452348-G-C | Uncertain significance (Feb 10, 2022) | |||
11-121452360-C-T | Uncertain significance (May 31, 2021) | |||
11-121452363-G-C | Uncertain significance (Dec 01, 2023) | |||
11-121452371-T-G | not specified | Uncertain significance (Nov 09, 2021) | ||
11-121452394-G-A | Likely benign (Oct 08, 2021) | |||
11-121452399-C-T | not specified | Uncertain significance (Aug 30, 2021) | ||
11-121452407-G-C | Uncertain significance (Jul 29, 2023) | |||
11-121452435-T-G | Uncertain significance (Feb 21, 2022) | |||
11-121452437-C-T | not specified | Uncertain significance (Sep 16, 2021) | ||
11-121452443-G-A | Uncertain significance (Jul 03, 2022) | |||
11-121452446-A-G | not specified | Uncertain significance (Apr 20, 2024) | ||
11-121452464-G-T | Uncertain significance (Oct 06, 2023) | |||
11-121452467-C-G | SORL1-related disorder | Likely benign (Dec 11, 2023) | ||
11-121452468-G-C | Uncertain significance (Feb 25, 2023) | |||
11-121452491-G-C | Uncertain significance (Nov 22, 2023) | |||
11-121452532-G-C | Uncertain significance (Nov 17, 2021) | |||
11-121452532-G-T | Uncertain significance (Jan 20, 2024) | |||
11-121452540-G-C | Uncertain significance (Aug 10, 2023) | |||
11-121452543-G-A | not specified | Uncertain significance (May 24, 2024) | ||
11-121452558-C-T | Uncertain significance (Nov 20, 2023) | |||
11-121452568-G-A | not specified | Benign (Jan 26, 2024) | ||
11-121452588-A-G | not specified | Uncertain significance (Mar 07, 2023) | ||
11-121452603-A-T | not specified | Uncertain significance (Jun 10, 2024) | ||
11-121452606-T-C | Uncertain significance (Aug 22, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SORL1 | protein_coding | protein_coding | ENST00000260197 | 48 | 181491 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
7.66e-11 | 1.00 | 125655 | 0 | 93 | 125748 | 0.000370 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.03 | 1068 | 1.27e+3 | 0.840 | 0.0000738 | 14657 |
Missense in Polyphen | 388 | 533.62 | 0.72711 | 6113 | ||
Synonymous | 0.855 | 478 | 502 | 0.951 | 0.0000320 | 4109 |
Loss of Function | 6.85 | 42 | 124 | 0.337 | 0.00000672 | 1379 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000762 | 0.000762 |
Ashkenazi Jewish | 0.000298 | 0.000298 |
East Asian | 0.000273 | 0.000272 |
Finnish | 0.000237 | 0.000231 |
European (Non-Finnish) | 0.000479 | 0.000466 |
Middle Eastern | 0.000273 | 0.000272 |
South Asian | 0.000163 | 0.000163 |
Other | 0.000654 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Likely to be a multifunctional endocytic receptor, that may be implicated in the uptake of lipoproteins and of proteases. Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. Binds the receptor- associated protein (RAP). Could play a role in cell-cell interaction. Involved in APP trafficking to and from the Golgi apparatus. It probably acts as a sorting receptor that protects APP from trafficking to late endosome and from processing into amyloid beta, thereby reducing the burden of amyloidogenic peptide formation. Involved in the regulation of smooth muscle cells migration, probably through PLAUR binding and decreased internalization. {ECO:0000269|PubMed:14764453, ECO:0000269|PubMed:16174740}.;
- Disease
- DISEASE: Alzheimer disease (AD) [MIM:104300]: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C- terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. {ECO:0000269|PubMed:21220680, ECO:0000269|PubMed:22472873, ECO:0000269|PubMed:23565137}. Note=The gene represented in this entry is involved in disease pathogenesis.;
- Pathway
- Metabolism of proteins;Amyloid fiber formation
(Consensus)
Intolerance Scores
- loftool
- 0.0875
- rvis_EVS
- -2.34
- rvis_percentile_EVS
- 1.16
Haploinsufficiency Scores
- pHI
- 0.802
- hipred
- N
- hipred_score
- 0.476
- ghis
- 0.554
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.882
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sorl1
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); muscle phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- protein targeting;protein targeting to lysosome;lipid transport;post-Golgi vesicle-mediated transport;receptor-mediated endocytosis;cholesterol metabolic process;regulation of smooth muscle cell migration;negative regulation of protein binding;negative regulation of protein oligomerization;protein localization to Golgi apparatus;negative regulation of MAP kinase activity;cellular protein metabolic process;protein retention in Golgi apparatus;positive regulation of protein catabolic process;negative regulation of neurogenesis;protein maturation;positive regulation of protein exit from endoplasmic reticulum;negative regulation of neuron death;negative regulation of amyloid-beta formation;positive regulation of choline O-acetyltransferase activity;negative regulation of tau-protein kinase activity;positive regulation of ER to Golgi vesicle-mediated transport;positive regulation of early endosome to recycling endosome transport;negative regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process;negative regulation of metalloendopeptidase activity involved in amyloid precursor protein catabolic process;positive regulation of protein localization to early endosome;negative regulation of neurofibrillary tangle assembly;positive regulation of endocytic recycling
- Cellular component
- Golgi membrane;extracellular space;nuclear envelope lumen;endosome;early endosome;endoplasmic reticulum;Golgi apparatus;trans-Golgi network;integral component of plasma membrane;endosome membrane;membrane;Golgi cisterna;low-density lipoprotein particle;recycling endosome;extracellular exosome
- Molecular function
- amyloid-beta binding;transmembrane signaling receptor activity;low-density lipoprotein particle receptor activity;protein binding;low-density lipoprotein particle binding;ADP-ribosylation factor binding